Journal
DIABETES OBESITY & METABOLISM
Volume 15, Issue 3, Pages 258-263Publisher
WILEY
DOI: 10.1111/dom.12022
Keywords
ss-cell; insulin therapy
Categories
Funding
- Sanofi-Aventis
- NovoNordisk
- MSD
- Eli Lilly
- Novartis
Ask authors/readers for more resources
Aim Postprandial insulin pulsatility is impaired in patients with type 2 diabetes, but the effects of exogenous insulin therapy on pulsatile insulin secretion are not known. We addressed, whether pulsatile insulin secretion is related to glycaemic control, whether basal insulin supplementation increases postprandial insulin secretion, and if so, is this accomplished by a specific improvement in pulsatile insulin secretion? Methods Fourteen patients with type 2 diabetes underwent a mixed meal test before and after an 8-week treatment period with insulin glargine. Glucose, insulin and C-peptide levels were measured, and insulin pulsatility was determined by deconvolution analysis. Results Insulin treatment lowered fasting glycaemia from 179.6 +/- 7.5?mg/dl to 117.6 +/- 6.5?mg/dl (p?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available